Clinics in Jalan Ampang | Kuala Lumpur | KL


CHONG DISPENSARY
TEL: (03) 2078 0397
BANGUNAN ENG CHOON
55-59, 2ND FLR, JALAN AMPANG
50450 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 8.30AM-1PM, 2PM-
4.45PM
SAT: 8.30AM-12.45PM
SUN CLOSED
P/HOLIDAY: CLOSED



DR MOHAMED MYDIN & RAKANRAKAN
TEL: (03) 425 70869
383-C JALAN AMPANG
50450 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 8AM-11PM
SAT - SUN: 8AM-11PM
P/HOLIDAY: 8AM-11PM



KELINIK NG DAN LEE
TEL: (03) 425 60764
337 JALAN AMPANG 4TH MILE
50450 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 8AM-9PM
SAT - SUN: 8AM-9PM
P/HOLIDAY: 8AM-9PM



KLINIK ANTHONY
TEL: (03) 425 72875
365-1 4TH MILE JALAN AMPANG
50450 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 9AM-5PM , 7-9PM
SAT: 9AM-5PM SUN : 9AM-1PM
P/HOLIDAY: 9AM-1PM



KLINIK IAN ONG
TEL: (03) 271 57488
3A-09, PLAZA 138
NO 138 JALAN AMPANG
50450 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 8.45AM-5PM.
SAT: :9AM-12.45PM SUN:



KLINIK MEDICAL ASSOCIATES
TEL: (03) 207 03585
805C, TINGKAT 8, WISMA HAMZAH KWONG HING
NO 1, LEBOH AMPANG
50100 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 9AM-1PM, 2PM-5PM
8.30AM-1PM (EXC 1ST SATURDAY)
SUN CLOSED
P/HOLIDAY: CLOSED



KLINIK MEDIVIRON
TEL: (03) 425 32331
78, LORONG MAMANDA 1
AMPANG POINT, AMPANG
68000 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
DAILY: 24 HRS



KLINIK SALMA
TEL: (03) 216 15442
168, AMPANG PARK
JALAN AMPANG
50450 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 9AM-8.30PM
SAT: 9AM-5PM SUN: 10AM-1PM
P/HOLIDAY: CALL TO CONFIRM



KLINIK WISMA
SUITE 18.02, TINGKAT 18,
WISMA MCA
163 JALAN AMPANG
50450 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 9AM-5PM
SAT: 9AM-5PM SUN CLOSED
P/HOLIDAY: CLOSED



KLINIK YONG
6TH FLOOR BANGUNAN MBSB
13-15 LEBUH AMPANG
50100 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 9AM-1PM, 2-5PM
SAT : 9AM-1PM. SUN : CLOSED
P/HOLIDAY: CLOSED



KOH DISPENSARY SDN BHD
SUITE 21.02A LEVEL 21, MENARA
CITIBANK
165 JALAN AMPANG
50450 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 9AM-1PM, 2-5PM
SAT: :9AM-1PM SUN: CLOSED
P/HOLIDAY: CLOSED



LIAN NORANA CLINIC
SUITE 905C, WISMA HAMZAH
KWONG HING
NO 1 LEBOH AMPANG
50100 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 8.45AM-12.45PM,2PM-
4.45PM
SAT: 9.00AM-12.30PM,
SUN CLOSED
P/HOLIDAY: CLOSED



POLIKLINIK KUMPULAN CITY
LOT 1.02 GROUND FLOOR,
WISMA CENTRAL
JALAN AMPANG
50450 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 9AM-5PM
SAT: 9AM-1PM SUN CLOSED
P/HOLIDAY: CLOSED



SUNDARAM DISPENSARY
TEL: (03) 238 5913
73, LEBOH AMPANG
50100 KUALA LUMPUR, WILAYAH
PERSEKUTUAN
MON - FRI: 9AM-1.30PM, 3.30-7PM
SUN 9AM-1.30PM
P/HOLIDAY: 9AM-1.30PM

Clinics in Jalan Ampang, Kuala Lumpur; updated 25th Oct 2011

Comments

Post a Comment

Popular posts from this blog

GLP-1 Cost and Coverage 2026: Self-Pay, Insurance and Pill Prices

Image
By Dr. Frank Yap, MD  |  Last reviewed: November 2026  |  Purpose: evidence and cost education, not individual medical or financial advice Quick Answer In November 2026, advertised US self-pay prices for weight-management GLP-1s start at $149 per month (Wegovy pill 1.5 mg, Foundayo 0.8 mg) and run to $449 for higher-dose Zepbound KwikPen, down from list prices above $1,000. The White House announced the Eli Lilly and Novo Nordisk pricing agreements on November 6, 2025 and launched TrumpRx.gov on February 5, 2026; those announcements are the policy backdrop, but your price still depends on product, dose, insurance and offer expiry (several end December 31, 2026 ). Eligible Medicare patients may pay $50 per month through the GLP-1 Bridge (July 1, 2026 to December 31, 2027). This guide covers prescription GLP-1 and related weight-management medications in the United States. Prices are ...
Read more

GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

Image
Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: November 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management.  The 5 November 2026 Science special issue (“GLP-1 and Beyond”) examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyond classic metabolic disease—especially the brain—while highlighting the shift toward multi-receptor agents. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regu...
Read more

GLP-1 for Knee Osteoarthritis: Pain Relief, Weight Loss, PRP, Stem Cells or Surgery?

Image
Updated November 2026 | By the OneDayMD Research Team | Reviewed by Dr Frank Yap, MD Can GLP-1 medications such as semaglutide help people with knee osteoarthritis avoid injections or knee replacement? The answer is more encouraging than it was a few years ago, but important uncertainties remain. A major randomized trial published in the New England Journal of Medicine found that semaglutide improved both body weight and knee osteoarthritis symptoms in people with obesity. In September 2026, the American College of Rheumatology (ACR) added a conditional recommendation for GLP-1 receptor agonists to help people with knee osteoarthritis and obesity achieve an appropriate weight, alongside diet and exercise. However, losing weight, relieving pain, regenerating damaged cartilage and avoiding surgery are different outcomes. Evidence supporting one does not automatically prove the others. This guide compares GLP-1 medications with platelet-rich plasma (PRP), stem-cell injectio...
Read more

Ozempic Pill vs Wegovy Pill vs Foundayo: Comparison, Price and Side Effects (2026)

Image
Last updated: November 2026  |  By: One Day Advisor Editorial Team Which oral GLP-1 is for diabetes, which is for weight loss, what each costs, and who is winning the oral obesity market Quick Answer The Ozempic pill and the Wegovy pill are both oral semaglutide from Novo Nordisk, but only the Wegovy pill is approved for weight loss. The Ozempic pill is approved for type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes. Foundayo (Eli Lilly’s orforglipron) is a different, non-peptide drug approved for weight management. Self-pay prices start at $149 per month for all three. In weight-loss prescriptions the Wegovy pill leads Foundayo about 2.9 to 1 (about 183,000 vs 63,110 weekly scripts, week ended October 23, 2026). Foundayo needs no fasting or water rules; the two semaglutide pills do. Jump to Ozemp...
Read more

Peptide Therapy in 2026: What the Evidence Says About BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon

Image
Updated:  November 2026 | Editorial team: OneDayMD | Purpose: Evidence and safety education Peptides are increasingly promoted for faster injury recovery, muscle growth, fat loss, better skin, improved sexual function, sleep and “anti-aging.” Some peptide medicines have transformed modern care. Others are experimental compounds with promising laboratory findings but little reliable evidence in people. The word peptide describes a type of molecule. It is not a guarantee of safety, effectiveness, purity or regulatory approval. Insulin and semaglutide are peptides; so are unapproved compounds sold online as “research chemicals.” Their evidence, manufacturing standards and medical uses are not interchangeable. Key takeaways Approved peptide medicines are not the same as research peptides. Approved medicines have been evaluated for specific uses, doses and risks. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon remain inves...
Read more

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Home › GLP-1 Hub > GLP-1 Muscle Loss By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The ...
Read more

GLP-1 & AI Research Monitor 2026–2027

Image
WEEKLY RESEARCH MONITOR EVIDENCE-FOCUSED AI IN HEALTHCARE Reporting period: 2–9 November 2026 Report date: 9 November 2026 Coverage: GLP-1 therapies, next-generation incretins, artificial intelligence, precision obesity treatment, clinical trials, pharmacovigilance and digital health. About this research monitor The GLP-1 & AI Research Monitor is an independent research initiative from OneDayMD and GLP-1 Advisor. Its purpose is to track developments at the intersection of metabolic medicine, pharmaceutical innovation, artificial intelligence and digital healthcare. The monitor covers both established GLP-1 receptor agonists and emerging therapies, while investigating how artificial intelligence may improve drug discovery, treatment selection, patient monitoring, medication adherence and safety surveillance. Rather than simply reporting pharmaceutical announcements, the objective is to evaluate what the evidence actually demonstrates, identify research...
Read more

GLP-1 and Beyond: What the Evidence Shows on Brain Health, Cancer Risk, Addiction, Knee Osteoarthritis and Next-Generation Drugs (2026)

Image
Quick Answer This article examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyond classic metabolic disease—especially the brain—while highlighting the shift toward multi-receptor agents. Observational data link these drugs to lower dementia risk in some metabolic populations, but large Alzheimer’s trials (EVOKE/EVOKE+) have not shown clinical benefit. Cancer-risk reductions appear largely tied to weight loss and related changes rather than proven intrinsic anticancer activity. Addiction research is promising but early. Key limitations include gastrointestinal effects, muscle loss, variable response, and weight regain after stopping. The issue stresses the need for better mechanistic studies, rigorous trials, and broader access strategies. What the Science GLP-1 Special Issue Covers The 5 November 2026 Science special issue (“GLP-1 and Beyond”) examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyon...
Read more

GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy

Image
Updated November 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health wit...
Read more

GLP-1 Clinical Trials & Research Tracker 2026

Semaglutide, tirzepatide, retatrutide, CagriSema, orforglipron and next-generation obesity medicines Research snapshot: 3 November 2026 · Curated Phase 3, pivotal and landmark human studies · Last editorial review: 3 November 2026 This tracker follows major clinical studies of GLP-1 receptor agonists and related incretin-based medicines across obesity, type 2 diabetes, cardiovascular disease, kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea and other obesity-related complications. It is designed as a research navigation tool: each entry links to its ClinicalTrials.gov record and, where available, a peer-reviewed paper, regulatory source or clearly identified sponsor announcement. The tracker distinguishes completed trials from posted results and distinguishes peer-reviewed evidence from sponsor-reported topline findings. How to use this tracker: Search by medicine, trial acronym, NCT number or condition. Use the dropdowns...
Read more